Lava Therapeutics Bv Stock Price, News & Analysis

LAVA Therapeutics (Nasdaq: LVTX) announced that Stephen Hurly, CEO, will participate in a fireside chat at the UBS Global Healthcare Conference 2022.

Event Details:

• Date: May 23, 2022
• Time: 4:15-4:45 PM ET

A live webcast and replay will be available on the company's investor relations website. LAVA Therapeutics focuses on developing its proprietary Gammabody™ platform targeting cancer treatment.

LAVA Therapeutics (Nasdaq: LVTX) announced it will present updated interim data from the dose escalation phase of its Phase 1/2a clinical trial for LAVA-051, targeted at relapsed or refractory chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). This presentation will take place at the 2022 ASCO Annual Meeting in Chicago from June 3-7, 2022. The session is scheduled for June 5, and will be led by Dr. Benjamin Winograd, LAVA's Chief Medical Officer. The trial seeks to evaluate the effectiveness of LAVA-051 as a bispecific gamma delta T-cell engager.

LAVA Therapeutics N.V. (Nasdaq: LVTX) reported promising developments in its clinical trials for LAVA-051 and LAVA-1207, with initial safety data showing no dose-limiting toxicities. The company also introduced a new pipeline candidate, LAVA-1266, targeting hematological malignancies. As of December 31, 2021, LAVA's financial position strengthened with cash and investments totaling $133.2 million, a significant increase from $15.8 million in 2020. However, the company reported a net loss of $45.3 million for 2021, reflecting rising operational expenses.

LAVA Therapeutics N.V. (Nasdaq: LVTX) announced that CEO Stephen Hurly will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, from 8:40 – 9:10 a.m. ET. The presentation will provide an overview of the company, which develops bispecific gamma delta T cell engagers (bsTCEs) for cancer treatment. The conference will be virtual, and a recording will be available post-event on their website. LAVA is currently enrolling patients in a Phase 1/2a study for LAVA-051 and LAVA-1207 to treat hematological malignancies and mCRPC, respectively.

LAVA Therapeutics (Nasdaq: LVTX) recently shared promising preliminary data from its Phase 1/2a clinical trial of LAVA-051, an investigational Gammabody™ designed to engage Vγ9Vδ2 T cells for cancer treatment. The initial cohorts demonstrated no dose-limiting toxicities or cytokine release syndrome (CRS), indicating a favorable safety profile. Observations showed increased receptor occupancy and T cell activation with dose escalation. Future data is expected in Q2 2022, and LAVA plans to file an IND application with the FDA to include U.S. patients.

LAVA Therapeutics has initiated the first patient dosing in its Phase 1/2a clinical trial for LAVA-1207, a bispecific T cell engager targeting metastatic castration-resistant prostate cancer (mCRPC). This trial aims to evaluate the safety, tolerability, and preliminary efficacy of LAVA-1207, which has shown promising preclinical results. The open-label trial will commence in Europe before expanding to the U.S. LAVA-1207 offers hope for patients with limited treatment options, addressing a significant unmet need in prostate cancer therapy.

LAVA Therapeutics N.V. (Nasdaq: LVTX) announced that Stephen Hurly, CEO, will present at the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 8:40 a.m. ET. This virtual event will provide insights into the company's bispecific gamma delta T cell engagers developed using its Gammabody™ platform. The company is currently enrolling patients for its Phase 1/2a clinical studies for LAVA-051 and LAVA-1207, targeting hematological malignancies and prostate cancer, respectively. Topline data from these studies is anticipated in 2022.

LAVA Therapeutics (Nasdaq: LVTX) announced encouraging results from preclinical data on its Gammabody™ platform, specifically for its lead solid tumor candidate, LAVA-1207, targeting metastatic castration-resistant prostate cancer (mCRPC). The bispecific antibody platform demonstrated potent anti-tumor activity while minimizing toxicity. Recruitment is underway for a Phase 1/2a trial to evaluate LAVA-1207's safety and efficacy. Non-human primate studies confirmed the safety and tolerability of its Gammabody™ technology, supporting its potential for enhanced therapeutic benefits.